Have a feature idea you'd love to see implemented?
Let us know!
CRVS Corvus Pharmaceuticals Inc
Price (delayed)
$7.68
Market cap
$480.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.44
Enterprise value
$466.25M
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells
Highlights
The debt has plunged by 65% YoY and by 33% from the previous quarter
Corvus Pharmaceuticals's equity has surged by 54% QoQ and by 3.5% YoY
The quick ratio has contracted by 25% YoY but it has grown by 8% from the previous quarter
Key stats
What are the main financial stats of CRVS
Market
Valuations
Earnings
Shares outstanding
62.55M
Market cap
$480.39M
Enterprise value
$466.25M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$22.62M
EBITDA
-$22.51M
Free cash flow
-$21.24M
Per share
Balance sheet
Liquidity
EPS
-$0.44
Free cash flow per share
-$0.36
Book value per share
$0.82
Revenue per share
$0
TBVPS
$1.08
Total assets
$64.56M
Total liabilities
$13.34M
Debt
$700,000
Equity
$51.23M
Working capital
$34.92M
Debt to equity
0.01
Current ratio
3.62
Quick ratio
3.55
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-44.8%
Return on equity
-54%
Return on invested capital
-76.9%
Return on capital employed
-44.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVS stock price
How has the Corvus Pharmaceuticals stock price performed over time
Intraday
1.59%
1 week
6.52%
1 month
48.26%
1 year
550.85%
YTD
336.36%
QTD
45.45%
Financial performance
How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.4M
Net income
-$22.62M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has increased by 42% YoY and by 9% QoQ
The operating income rose by 23% year-on-year
Growth
What is Corvus Pharmaceuticals's growth rate over time
Valuation
What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 48% YoY and by 14% QoQ
Corvus Pharmaceuticals's equity has surged by 54% QoQ and by 3.5% YoY
Efficiency
How efficient is Corvus Pharmaceuticals business performance
The company's return on assets rose by 24% YoY and by 12% QoQ
The ROE is up by 24% year-on-year and by 10% since the previous quarter
Corvus Pharmaceuticals's return on invested capital has increased by 12% YoY and by 3.3% QoQ
Dividends
What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVS.
Financial health
How did Corvus Pharmaceuticals financials performed over time
Corvus Pharmaceuticals's total liabilities has surged by 98% QoQ and by 56% YoY
The total assets has soared by 61% from the previous quarter and by 11% YoY
The debt is 99% less than the equity
The debt to equity has dropped by 75% year-on-year and by 67% since the previous quarter
The debt has plunged by 65% YoY and by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.